Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v1-EN
Language French English
Date Updated 2022-05-04 2022-04-25
Drug Identification Number 02416328 02416328
Brand name AUBAGIO AUBAGIO
Common or Proper name Teriflunomide tablets 14 mg Teriflunomide tablets 14 mg
Company Name SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC SANOFI GENZYME, A DIVISION OF SANOFI-AVENTIS CANADA INC
Ingredients TERIFLUNOMIDE TERIFLUNOMIDE
Strength(s) 14MG 14MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL ORAL ORAL
Packaging size 14 mg 14 mg
ATC code L04AA L04AA
ATC description IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS
Reason for shortage Other (Please describe in comments) Other (Please describe in comments)
Anticipated start date 2022-04-28 2022-04-28
Actual start date
Estimated end date 2022-05-11 2022-05-11
Actual end date 2022-05-03
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Manufacturing delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. Manufacturing delay. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date.
Health Canada comments